Copenhagen, Denmark - MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) announced that its self-developed VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System ("VitaFlow Liberty^®") has completed five pre-market implantations at Rigshospitalet (Copenhagen University Hospital) in Denmark. The surgery was conducted by cardiologist Dr. Ole De Backer and his team from Rigshospitalet, with Dr. Darren Mylotte, an Irish cardiology expert, serving as a special invited consultant. During the surgery, The valves of all five patients were released to the ideal position, and immediate postoperative imaging showed good valve morphology and position, with no perivalvular leakage or regurgitation, indicating the successful completion of the surgery. All patients recovered well and were discharged the following day.

Shanghai, China - MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) recently announced that following Alwide^® Plus Balloon Catheter, the second generation of balloon catheter, Its self-developed new generation Transcatheter Aortic Valve Implantation (" TAVI ") product VitaFlow Liberty^® Transcatheter Aortic Valve and Retrivable Delivery System (" VitaFlow Liberty^® ") has received marketing approval from the Russian State Food and Drug Regulatory Agency (RZN)

Shanghai, China — Recently, MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) has received marketing approval for its second-generation balloon catheter , Alwide^® Plus Balloon Catheter (hereinafter referred to as "Alwide^® Plus") from Russian State Food and Drug Administration(RZN).